vs

Side-by-side financial comparison of Silence Therapeutics plc (SLN) and Volato Group, Inc. (SOAR). Click either name above to swap in a different company.

Volato Group, Inc. is the larger business by last-quarter revenue ($24.9M vs $15.7M, roughly 1.6× Silence Therapeutics plc). Volato Group, Inc. runs the higher net margin — 14.5% vs -14.7%, a 29.2% gap on every dollar of revenue.

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

Volato Aeronaves also known as Volato Aeronaves e Compósitos Ltda is a Brazilian aircraft manufacturer.

SLN vs SOAR — Head-to-Head

Bigger by revenue
SOAR
SOAR
1.6× larger
SOAR
$24.9M
$15.7M
SLN
Higher net margin
SOAR
SOAR
29.2% more per $
SOAR
14.5%
-14.7%
SLN

Income Statement — Q1 FY2024 vs Q2 FY2025

Metric
SLN
SLN
SOAR
SOAR
Revenue
$15.7M
$24.9M
Net Profit
$-2.3M
$3.6M
Gross Margin
82.2%
15.2%
Operating Margin
-35.6%
3.5%
Net Margin
-14.7%
14.5%
Revenue YoY
13632.0%
Net Profit YoY
121.3%
EPS (diluted)
$-0.02
$0.75

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SLN
SLN
SOAR
SOAR
Q2 25
$24.9M
Q1 25
$25.5M
Q3 24
$38.5M
Q1 24
$15.7M
Q4 23
$3.2M
Q3 23
$3.7M
Q2 23
$13.0M
Q1 23
$15.7M
Net Profit
SLN
SLN
SOAR
SOAR
Q2 25
$3.6M
Q1 25
$455.0K
Q3 24
$-4.4M
Q1 24
$-2.3M
Q4 23
Q3 23
$-11.8M
Q2 23
$-9.9M
Q1 23
$-7.5M
Gross Margin
SLN
SLN
SOAR
SOAR
Q2 25
15.2%
Q1 25
17.6%
Q3 24
16.6%
Q1 24
82.2%
Q4 23
Q3 23
8.7%
Q2 23
-24.2%
Q1 23
-10.8%
Operating Margin
SLN
SLN
SOAR
SOAR
Q2 25
3.5%
Q1 25
9.9%
Q3 24
5.5%
Q1 24
-35.6%
Q4 23
Q3 23
-50.2%
Q2 23
-71.3%
Q1 23
-50.5%
Net Margin
SLN
SLN
SOAR
SOAR
Q2 25
14.5%
Q1 25
1.8%
Q3 24
-11.5%
Q1 24
-14.7%
Q4 23
Q3 23
-323.6%
Q2 23
-75.8%
Q1 23
-48.0%
EPS (diluted)
SLN
SLN
SOAR
SOAR
Q2 25
$0.75
Q1 25
$0.03
Q3 24
$-3.76
Q1 24
$-0.02
Q4 23
Q3 23
$-0.71
Q2 23
$-0.86
Q1 23
$-0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SLN
SLN
SOAR
SOAR
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
Stockholders' EquityBook value
$156.8M
$-7.1M
Total Assets
$13.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Stockholders' Equity
SLN
SLN
SOAR
SOAR
Q2 25
$-7.1M
Q1 25
$-15.8M
Q3 24
$-19.6M
Q1 24
$156.8M
Q4 23
$14.8M
Q3 23
$-34.8M
Q2 23
$-23.0M
Q1 23
$-13.2M
Total Assets
SLN
SLN
SOAR
SOAR
Q2 25
$13.0M
Q1 25
$23.4M
Q3 24
$47.9M
Q1 24
Q4 23
$71.7M
Q3 23
$70.4M
Q2 23
$70.9M
Q1 23
$289.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SLN
SLN
SOAR
SOAR
Operating Cash FlowLast quarter
$-9.1M
$848.0K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
0.0%
Cash ConversionOCF / Net Profit
0.24×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SLN
SLN
SOAR
SOAR
Q2 25
$848.0K
Q1 25
$-312.0K
Q3 24
$-3.1M
Q1 24
$-9.1M
Q4 23
$-30.4M
Q3 23
$-10.9M
Q2 23
$-5.6M
Q1 23
$-7.6M
Free Cash Flow
SLN
SLN
SOAR
SOAR
Q2 25
Q1 25
Q3 24
$-3.2M
Q1 24
Q4 23
$-31.0M
Q3 23
$-11.1M
Q2 23
$-5.9M
Q1 23
$-7.9M
FCF Margin
SLN
SLN
SOAR
SOAR
Q2 25
Q1 25
Q3 24
-8.2%
Q1 24
Q4 23
-958.0%
Q3 23
-304.7%
Q2 23
-45.6%
Q1 23
-50.3%
Capex Intensity
SLN
SLN
SOAR
SOAR
Q2 25
0.0%
Q1 25
0.0%
Q3 24
0.1%
Q1 24
0.0%
Q4 23
19.7%
Q3 23
7.4%
Q2 23
2.2%
Q1 23
1.7%
Cash Conversion
SLN
SLN
SOAR
SOAR
Q2 25
0.24×
Q1 25
-0.69×
Q3 24
Q1 24
Q4 23
Q3 23
Q2 23
Q1 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons